Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Research
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity Policy, Research
Drivers of Obesity Commercial Determinants of Health: Implications for Health Interventions Prof. Emma Boyland University of Liverpool, United Kingdom Watch now
